Where to start with systemic melanoma therapy?
Year: 2014
Type: editorial
Abstract: Melanoma ManagementVol. 1, No. 1 EditorialWhere to start with systemic melanoma therapy?Geoffrey T Gibney, Vernon K Sondak & Keiran SM SmalleyGeoffrey T Gibney The Department of Cutaneous Oncology, The Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA, Vernon K Sondak The Department of Cutaneous Oncology, The Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA & Keiran SM Smalley*Author for correspondence: E-mail Address: [email protected] The Department of Cutaneous Oncology, The Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USA The Department of Molecular Oncology, The Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL, USAPublished Online:5 Sep 2014https://doi.org/10.2217/mmt.14.3AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: BRAFcombination therapyCTLA-4melanomaNRASPD-1References1 Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949–954 (2002).Crossref, Medline, CAS, Google Scholar2 Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem. Pharmacol. 82(3), 201–209 (2011).Crossref, Medline, CAS, Google Scholar3 Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, Phase 3 randomised controlled trial. Lancet 380(9839), 358–365 (2012).Crossref, Medline, CAS, Google Scholar4 Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507–2516 (2011).Crossref, Medline, CAS, Google Scholar5 Chapman PB, Hauschild A, Robert C et al. Updated overall survival (OS) results for BRIM-3, a Phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E-mutated melanoma. J. Clin. Oncol. (Suppl.), Abstract 8502 (2012).Medline, Google Scholar6 Hauschild A, Grob JJ, Demidov LV et al. An update on BREAK-3, a Phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J. Clin. Oncol. 31(Suppl.), Abstract 9013 (2013).Google Scholar7 Paraiso KH, Fedorenko IV, Cantini LP et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102(12), 1724–1730 (2010).Crossref, Medline, CAS, Google Scholar8 Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367(18), 1694–1703 (2012).Crossref, Medline, CAS, Google Scholar9 Kim K, Amavaradi RK, Flaherty K et al. Significant long-term survival benefit demonstrated with vemurafenib in ongoing Phase I study. Pigm. Cell Melanoma R. 25(6), 866 (2012).Google Scholar10 Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).Crossref, Medline, CAS, Google Scholar11 Schadendorf D, Hodi FS, Robert C et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Ann. Oncol. European Cancer Congress, LBA 24 (2013).Google Scholar12 Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).Crossref, Medline, CAS, Google Scholar13 Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134–144 (2013).Crossref, Medline, CAS, Google Scholar14 Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122–133 (2013).Crossref, Medline, CAS, Google Scholar15 Kaufman HL, Kirkwood JM, Hodi FS et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat. Rev. Clin. Oncol. 10(10), 588–598 (2013).Crossref, Medline, CAS, Google Scholar16 Ascierto PA, Schadendorf D, Berking C et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 14(3), 249–256 (2013).Crossref, Medline, CAS, Google Scholar17 Ascierto PA, Simeone E, Chiarion-Sileni V et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of ipilimumab expanded access programme (EAP). J. Clin. Oncol. Abstract 9035 (2013).Crossref, Google Scholar18 Boni A, Cogdill AP, Dang P et al. Selective BRAF V600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70(13), 5213–5219 (2010).Crossref, Medline, CAS, Google Scholar19 Frederick DT, Piris A, Cogdill AP et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19(5), 1225–1231 (2013).Crossref, Medline, CAS, Google Scholar20 Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368(14), 1365–1366 (2013).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 1, No. 1 Follow us on social media for the latest updates Metrics Downloaded 84 times History Published online 5 September 2014 Published in print August 2014 Information© Future Medicine LtdKeywordsBRAFcombination therapyCTLA-4melanomaNRASPD-1Financial & competing interests disclosureWork in the Smalley laboratory is supported by R01 CA161107-01 from the NIH, and SPORE grant CA168536. VK Sondak is a paid consultant for Merck, GlaxoSmithKline, Bristol Myers Squibb, Novartis and Provectus. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Source: Melanoma Management
DOI: 10.2217/mmt.14.3
Institution: Moffitt Cancer Center
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2067642499